For example, engagers targeting NK cells to CD30+ lymphomas, CD33+ myelodysplastic syndrome, CD133+ colon cancer, CLEC12A+ and CD33+ AML are all in clinical development. The gene discussed is PROM1; the disease is malignant colon neoplasm.